Who are Mepolizumab Injection [Nucala]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mepolizumab SC, Mepolizumab 100 milligrams, Liquid mepolizumab, Mepolizumab IV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mepolizumab-injection-nucala.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Mepolizumab Injection [Nucala] — Competitive Intelligence Brief

Mepolizumab Injection [Nucala] (Mepolizumab Injection [Nucala]) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-5 antagonist monoclonal antibody. Area: Immunology / Respiratory.

marketed IL-5 antagonist monoclonal antibody IL-5 (Interleukin-5) Immunology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Mepolizumab Injection [Nucala] (Mepolizumab Injection [Nucala]) — KU Leuven. Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mepolizumab Injection [Nucala] TARGET	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Mepolizumab SC	Mepolizumab SC	GlaxoSmithKline	phase 3	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Mepolizumab 100 milligrams	Mepolizumab 100 milligrams	GlaxoSmithKline	phase 3	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Liquid mepolizumab	Liquid mepolizumab	GlaxoSmithKline	phase 3	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Mepolizumab IV	Mepolizumab IV	GlaxoSmithKline	phase 3	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-5 antagonist monoclonal antibody class)

GlaxoSmithKline · 4 drugs in this class
KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mepolizumab Injection [Nucala] — Competitive Intelligence Brief. https://druglandscape.com/ci/mepolizumab-injection-nucala. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab